Targeted Disease(s):
COPD

Purpose of Study:

This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.

Study Dates:
May 19, 2022 - March 20, 2025

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Sanofi and Regeneron

Sponsors:

Sanofi and Regeneron

Contact:

Phone: 800-633-1610, option 6
tEmail: [email protected]

ClinicalTrails.gov Identifier:
NCT05326412

Register for Trial
Asthma Basics Workshop - National
, | Apr 17, 2024
Asthma Basics Workshop - National
, | May 07, 2024